TopiVert is a clinical-stage biotechnology company developing narrow spectrum kinase inhibitors (NSKIs) as novel, locally-acting medicines for the local treatment of chronic inflammatory diseases of the gastrointestinal tract and eye.
NSKIs are novel small molecules that are potent inhibitors of a range of kinases involved in the inflammatory response. They are designed to have low bioavailability, which reduces their exposure to many of the body’s healthy tissues, thereby enhancing their safety and tolerability profiles. Together, these attributes make NSKIs ideal treatment candidates for chronic inflammatory diseases where long-term therapy demands a sustained effect accompanied by excellent safety and tolerability.
TopiVert’s most advanced drug candidate, TOP1288 for the treatment of ulcerative colitis, has successfully completed Phase I development.
The company was founded in December 2011, following an £8.0 million funding round jointly led by Innovations and SV Life Sciences. In December 2013, TopiVert raised a further £17.0 million in a funding with new investors Johnson & Johnson Development Corporation and Neomed Management, joining the syndicate alongside SV Life Sciences and the Group.